PMID- 28475118
OWN - NLM
STAT- MEDLINE
DCOM- 20180208
LR  - 20181113
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 18
IP  - 5
DP  - 2017 May 5
TI  - Effects of Gelatin Hydrogel Containing Anti-Transforming Growth Factor-beta Antibody 
      in a Canine Filtration Surgery Model.
LID - 10.3390/ijms18050985 [doi]
LID - 985
AB  - In this present study, we investigated the effect of a controlled release of 
      anti-transforming growth factor beta (TGF-beta) antibody on intraocular pressure (IOP), 
      bleb formation, and conjunctival scarring in a canine glaucoma filtration surgery 
      model using gelatin hydrogel (GH). Glaucoma surgery models were made in 14 eyes 
      of 14 beagles and divided into the following two groups: (1) subconjunctival 
      implantation of anti-TGF-beta antibody-loaded GH (GH-TGF-beta group, n = 7), and (2) 
      subconjunctival implantation of GH alone (GH group, n = 7). IOP and bleb features 
      were then assessed in each eye at 2- and 4-weeks postoperative, followed by 
      histological evaluation. We found that IOP was significantly reduced at 4-weeks 
      postoperative in the two groups (p < 0.05) and that IOP in the GH-TGF-beta-group 
      eyes was significantly lower than that in the GH-group eyes (p = 0.006). In 
      addition, the bleb score at 4-weeks postoperative was significantly higher in the 
      GH-TGF-beta group than in the GH group (p < 0.05), and the densities of fibroblasts, 
      proliferative-cell nuclear antigen (PCNA)-positive cells, mast cells, and 
      TGF-beta-positive cells were significantly lower in the GH-TGF-beta group than in the 
      GH group. The findings of this study suggest that, compared with the GH-group 
      eyes, implantation of anti-TGF-beta antibody-loaded GH maintains IOP reduction and 
      bleb formation by suppressing conjunctival scarring due to the proliferation of 
      fibroblasts for a longer time period via a sustained release of anti-TGF-beta 
      antibody from GH.
FAU - Maeda, Michiko
AU  - Maeda M
AD  - Department of Ophthalmology, Osaka Medical College, Takatsuki-City, Osaka 
      569-8686, Japan. opt182@osaka-med.ac.jp.
FAU - Kojima, Shota
AU  - Kojima S
AD  - Department of Ophthalmology, Osaka Medical College, Takatsuki-City, Osaka 
      569-8686, Japan. shota@osaka-med.ac.jp.
FAU - Sugiyama, Tetsuya
AU  - Sugiyama T
AD  - Department of Ophthalmology, Osaka Medical College, Takatsuki-City, Osaka 
      569-8686, Japan. tsugiyama@osaka-med.ac.jp.
AD  - Nakano Eye Clinic of Kyoto Medical Cooperative, Kyoto 604-8404, Japan. 
      tsugiyama@osaka-med.ac.jp.
FAU - Jin, Denan
AU  - Jin D
AD  - Department of Innovative Medicine, Osaka Medical College, Takatsuki-City, Osaka 
      569-8686, Japan. pha012@osaka-med.ac.jp.
FAU - Takai, Shinji
AU  - Takai S
AD  - Department of Innovative Medicine, Osaka Medical College, Takatsuki-City, Osaka 
      569-8686, Japan. pha010@osaka-med.ac.jp.
FAU - Oku, Hidehiro
AU  - Oku H
AD  - Department of Ophthalmology, Osaka Medical College, Takatsuki-City, Osaka 
      569-8686, Japan. opt025@osaka-med.ac.jp.
FAU - Kohmoto, Ryohsuke
AU  - Kohmoto R
AD  - Department of Ophthalmology, Osaka Medical College, Takatsuki-City, Osaka 
      569-8686, Japan. ryousuke0218@hotmail.co.jp.
FAU - Ueki, Mari
AU  - Ueki M
AD  - Department of Ophthalmology, Osaka Medical College, Takatsuki-City, Osaka 
      569-8686, Japan. opt089@osaka-med.ac.jp.
FAU - Ikeda, Tsunehiko
AU  - Ikeda T
AD  - Department of Ophthalmology, Osaka Medical College, Takatsuki-City, Osaka 
      569-8686, Japan. tikeda@osaka-med.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20170505
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antibodies)
RN  - 0 (Transforming Growth Factor beta)
RN  - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate)
RN  - 9000-70-8 (Gelatin)
SB  - IM
MH  - Animals
MH  - Antibodies/administration & dosage/immunology/*therapeutic use
MH  - Dogs
MH  - Gelatin/*chemistry
MH  - Hydrogel, Polyethylene Glycol Dimethacrylate/*chemistry
MH  - Postoperative Complications
MH  - Trabeculectomy/adverse effects/*methods
MH  - Transforming Growth Factor beta/*immunology
PMC - PMC5454898
OTO - NOTNLM
OT  - beagles
OT  - gelatin hydrogel
OT  - glaucoma
OT  - trabeculectomy
OT  - transforming growth factor-beta
COIS- The authors declare no conflict of interest.
EDAT- 2017/05/06 06:00
MHDA- 2018/02/09 06:00
PMCR- 2017/05/01
CRDT- 2017/05/06 06:00
PHST- 2017/04/03 00:00 [received]
PHST- 2017/04/27 00:00 [revised]
PHST- 2017/05/02 00:00 [accepted]
PHST- 2017/05/06 06:00 [entrez]
PHST- 2017/05/06 06:00 [pubmed]
PHST- 2018/02/09 06:00 [medline]
PHST- 2017/05/01 00:00 [pmc-release]
AID - ijms18050985 [pii]
AID - ijms-18-00985 [pii]
AID - 10.3390/ijms18050985 [doi]
PST - epublish
SO  - Int J Mol Sci. 2017 May 5;18(5):985. doi: 10.3390/ijms18050985.